Replies to post #17240 on Momenta Pharmaceuticals, Inc. (MNTA)

[alternatepatel]

1. $1.5b is too cheap for the only apparent contender that can potentially achieve interchangeability with Humira (selling $16b/year)

2. Rest of the pipe is worth as much as item 1, IMO.

You see, it's difficult to agree on a valuation.